Sobi, Selecta: Phase 3 DISSOLVE Program Of SEL-212 In Chronic Refractory Gout Meets Primary Goal
Swedish Orphan Biovitrum AB or Sobi (SWTUY.PK), a specialised biopharmaceutical company, and Selecta Biosciences, Inc. (SELB) announced Tuesday positive topline results from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout.
Selecta Biosciences Selecta Imm Selecta Biosciences Inc More Such Health News Swedish Orphan Biovitrum Chronic Refractory
Source: rttnews.com